Application of EGFR inhibitor reduces circulating tumor cells during transcatheter arterial embolization
Transcatheter arterial embolization (TAE) has been widely used in treating non-curative hepatocellular carcinoma (HCC). However, it is noticed that TAE may cause invasion of some cancer cells into circulation, resulting in distal metastasis and poor therapeutic outcome. Here, we aimed to reduce the side effects of TAE using the inhibitors for epidermal growth factor receptor (EGFR).
Transient hepatic artery ligation (HAL) was used as a mouse model for TAE. EGFR inhibitors were applied. Tumor size, presence of tumor cells in circulation, distal tumor formation, and activation of genes associated with tumor cell invasion and metastasis were analyzed.
Inhibitors for EGFR significantly reduced the size of primary tumor, presence of tumor cells in circulation, and distal tumor formation after HAL. Further studies showed that EGFR inhibition suppressed several genes associated with tumor cell invasion and metastasis, such as vascular endothelial growth factor-A, stromal cell-derived factor 1, and Slug.
EGFR inhibitor application may reduce circulating cancer cells during TAE and thus improve the therapy for advanced HCC.
KeywordsTranscatheter arterial embolization (TAE) Transient hepatic artery ligation (HAL) Hepatocellular carcinoma (HCC) Epidermal growth factor receptor (EGFR) Vascular endothelial growth factor-A (VEGF-A) Stromal cell-derived factor 1 (SDF-1) Slug
Compliance with ethical standards
Conflict of interest
The authors have declared that no competing interests exist.
The study was approved by the Local Ethics Committee of Zhongshan Hospital of Fudan University, China.
- 1.Verslype C, Van Cutsem E, Dicato M, Arber N, Berlin JD, Cunningham D, et al. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. Ann Oncol. 2009;20(Suppl 7):vii1–6. doi: 10.1093/annonc/mdp281.PubMedGoogle Scholar
- 4.Arizumi T, Ueshima K, Minami T, Kono M, Chishina H, Takita M, et al. Effectiveness of sorafenib in patients with transcatheter arterial chemoembolization (TACE) refractory and intermediate-stage hepatocellular carcinoma. Liver cancer. 2015;4(4):253–62. doi: 10.1159/000367743.CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Fu S, Chen S, Liang C, Liu Z, Zhu Y, Li Y, et al. Texture analysis of intermediate-advanced hepatocellular carcinoma: prognosis and patients’ selection of transcatheter arterial chemoembolization and sorafenib. Oncotarget. 2017;8(23):37855–65. doi: 10.18632/oncotarget.13675.CrossRefPubMedGoogle Scholar
- 8.Murakami M, Nagano H, Kobayashi S, Wada H, Nakamura M, Marubashi S, et al. Effects of pre-operative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma: implication of circulating cancer cells by detection of alpha-fetoprotein mRNA. Exp Ther Med. 2010;1(3):485–91. doi: 10.3892/etm_00000076.CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Lai HC, Yeh CC, Jeng LB, Huang SF, Liao PY, Lei FJ, et al. Androgen receptor mitigates postoperative disease progression of hepatocellular carcinoma by suppressing CD90+ populations and cell migration and by promoting anoikis in circulating tumor cells. Oncotarget. 2016;7(29):46448–65. doi: 10.18632/oncotarget.10186.CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Zhang B, Wang D, Ji TF, Shi L, Yu JL. Overexpression of lncRNA ANRIL up-regulates VEGF expression and promotes angiogenesis of diabetes mellitus combined with cerebral infarction by activating NF-kappaB signaling pathway in a rat model. Oncotarget. 2017;8(10):17347–59. doi: 10.18632/oncotarget.14468.PubMedGoogle Scholar
- 26.Chen WX, Zhang ZG, Ding ZY, Liang HF, Song J, Tan XL, et al. MicroRNA-630 suppresses tumor metastasis through the TGF-beta- miR-630-Slug signaling pathway and correlates inversely with poor prognosis in hepatocellular carcinoma. Oncotarget. 2016;7(16):22674–86. doi: 10.18632/oncotarget.8047.PubMedPubMedCentralGoogle Scholar
- 28.Lin WH, Yeh SH, Yeh KH, Chen KW, Cheng YW, Su TH, et al. Hypoxia-activated cytotoxic agent tirapazamine enhances hepatic artery ligation-induced killing of liver tumor in HBx transgenic mice. Proc Natl Acad Sci USA. 2016;113(42):11937–42. doi: 10.1073/pnas.1613466113.CrossRefPubMedPubMedCentralGoogle Scholar